CAMBRIDGE, Mass. -- (BUSINESS WIRE) -- OvaScienceSM, (NASDAQ: OVAS), a global life sciences company focused on the discovery, development and commercialization of new fertility treatments, today announced that the Company’s scientific Co-Founder, David Sinclair, Ph.D., has been selected for the 2014 TIME 100, TIME’s annual list of the 100 most influential people in the world. Dr. Sinclair’s extensive research on aging and the key role of mitochondria (the energy source for all cells) contributed to OvaScience’s foundational egg precursor cell (EggPCSM) technology platform. The Company expects to launch its first fertility product, AUGMENTSM, in international in vitro fertilization (IVF) clinics in 2014. AUGMENT is designed to improve egg quality and the success of IVF by enhancing mitochondrial function.
“We congratulate Dr. Sinclair on his recognition by TIME for his groundbreaking research on aging, which is enabling the development of new treatments for conditions of aging, such as infertility,” said Michelle Dipp, M.D., Ph.D., Chief Executive Officer of OvaScience. “Our team at OvaScience is working with Dr. Sinclair to gain further insights about the impact of aging on egg quality as we continue to develop treatments for female infertility.”
Dr. Sinclair is a Professor in the Department of Genetics at Harvard Medical School and a con-joint Professor in the Department of Physiology and Pharmacology at the University of New South Wales. Dr. Sinclair was recruited to Harvard Medical School in 1999 where his laboratory’s research has focused primarily on understanding the role of sirtuins in disease and aging, with associated interests in energy metabolism, mitochondria, neurodegeneration, and cancer. Dr. Sinclair is the co-Director of the Paul F. Glenn Laboratories for the Biological Mechanisms of Aging and a Senior Scholar of the Ellison Medical Foundation.
Dr. Sinclair has published more than 126 scientific papers. His December 2013 paper in Cell underscored the critical role of mitochondrial function in aging, and described certain molecules that can improve mitochondrial function, to which OvaScience has exclusive rights in fertility. Dr. Sinclair is the 2014 Australian Society for Medical Research (ASMR) medalist, an award which recognizes his career contributions to medical research, and an honor shared by past Nobel Prize winners. He is also the co-founder of several biotechnology companies and is on the scientific advisory board of several others.
Earlier in his career, Dr. Sinclair worked as a postdoctoral researcher at M.I.T. with Dr. Leonard Guarente where he co-discovered a cause of aging for yeast and the role of Sir2 in DNA repair and aging. He obtained his Ph.D. in Biochemistry and Molecular Genetics at the University of New South Wales, Sydney in 1995.
OvaScience (NASDAQ: OVAS) is a global life sciences company focused on the discovery, development and commercialization of new fertility treatments. The Company’s patented technology is based on the discovery of egg precursor cells (EggPCSM), which are found in the ovaries. By applying proprietary technology to identify and purify EggPCs, OvaScience is developing potential next generation in vitro fertilization (IVF) treatments. The Company currently has three fertility treatments in development: AUGMENTSM, which aims to improve egg quality and increase the success of IVF; OvaPrimeSM, designed to boost a woman’s egg reserve using her own EggPCs; and OvaTureSM, which seeks to create mature fertilizable eggs from a woman’s own EggPCs without the need for hormone injections. OvaScience’s team of scientists, physicians and advisers includes recognized leaders in the field of reproductive medicine. For more information, please visit www.ovascience.com and connect with us on Twitter and Facebook.
This press release includes forward-looking statements about the prospects for the Company’s technology in addressing female infertility, the Company’s strategy, future plans and prospects, the development and commercialization of the Company’s product candidates and the Company’s plans to launch AUGMENT in international IVF clinics in 2014. Any statements in this release about our strategy, plans, prospects and future expectations, financial position and operations, and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” ”aim,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including risks related to: our expectations regarding the regulatory approvals required for AUGMENT outside of the United States and our expectation that AUGMENT meets the requirements of a class of products exempt from premarket review and approval under applicable regulations in those countries where we plan to introduce AUGMENT in ACE clinics; the science underlying our product candidates (including AUGMENT, OvaPrime and OvaTure), which is unproven; our ability to obtain, maintain and protect intellectual property utilized by our products; our ability to obtain additional funding to support our activities; our dependence on third parties, including our dependence on Intrexon Corporation; the successful development of, and ability to obtain regulatory approval for, our product candidates; our ability to develop our product candidates, including AUGMENT, OvaPrime and OvaTure, on the timelines we expect, if at all; our ability to commercialize our product candidates, including AUGMENT and OvaPrime, on the timelines we expect, if at all; competition from others; and our short operating history; as well as those risks more fully discussed in the “Risk Factors” section of our most recently filed Quarterly Report on Form 10-Q or Annual Report on Form 10-K. The forward-looking statements contained in this press release reflect our current views with respect to future events. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements in the future, we specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing our view as of any date subsequent to the date hereof.